Performance in Delivering Research Date Agreed to Date Agreed recruit target Target met number of to recruit Committee Name of Trial number of number of within the Comments patients target number Status Reference patients patients agreed time available? of patients available
A Phase I-II evaluation of the safety and efficacy of the oral HSP90 inhibitor Debio 0932 in combination with standard of care in
first and second line therapy of patients with Stage IIIb or IV Non-small Cell Lung Cancer - the HALO study (HSP90 inhibition
A Randomized, Open-label, Single Dose, Two-way Cross-Over Study to Investigate the Relative
Commercial Xeloda? Tablets Following Oral Administrations in Adult Patients with S
A multicentre, open label, early stopping design, proof of concept study with tasquinimod in
advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in
Combination with Either Gemcitabine or Cisplatin and Etoposide in Subjects with Advanced Solid TumorsA Cancer Research UK Phase I Trial of AZD3965, a monocarboxylate
transporter 1 inhibitor (MCT1) in patients with advanced cancer.
A single-arm, open-label, phase II, multicentre study to assess the safety of
0449) in patients with locally advanced or metastatic basal cell carcinoma.
A Phase 1, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of Selumetinib
(AZD6244; ARRY-142886) in combination with first line chemotherapy regimens in patients with non-small cell lung cancer.
A randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the
DOPA in subjects with Parkinson?s disease exhibiting delayed gastric emptying
A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics, and
Levodopa Powder) in Patients with Parkinson's Disease and Motor Response Fluctuations ("Off" Episodes)
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the
Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease (Scarlett Road)
An open-label, Multicentre, Extension Study to Evaluate the Long-Term Safety
BIIB050) in Subjects With Amyotrophic Lateral Sclerosis
Efficacy and safety of 3 doses of S 38093 (2, 5 and 20 mg/day) versus placebo, in co-administration with donepezil (10 mg/day) in patients
with moderate Alzheimer?s Disease. A 24-week international, multi-centre, randomised, double-blind, placebo-controll
ENHANCE: A Prospective Long-term EvaluatioN of the Use of Permacol?
Biological Implant in tHe Repair of Complex AbdomiNal Wall CasEs
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of
Subjects with Primary Biliary Cirrhosis Who had an Inadequate Response to Ursodeoxycholic Acid (UDCA)
An open-label, multicenter, follow-up study to evaluate the long-term safety and efficacy of
Brivaracetam used as adjunctive treatment in subjects aged 16 years or older with Partial Onset Seizures
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study to
and Safety of Brivaracetam in Subjects (=16 to 80 Years Old) with Partial Onset SeizuresA prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron
deficiency anaemia in subjects with quiescent ulcerative colitis where oral ferrous preparations have failed or cannot be used (AEG
A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron
deficiency anaemia in subjects with quiescent Crohn's Disease where oral ferrous preparations have failed or cannot be used (AEGIS
Retreatment of recurrent contractures in joints effectively treated with AA4500 (Collagenase
Histolyticum) in an Auxilium sponsored phase 3 study in the United States, Australia and Europe.
A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 ?g Dexamethasone
Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients With Diabetic Macular Edema
A Prospective, Multi-Centre, Post Market, Single Arm Observational Study to Collect Clinical
Outcome Data on the Use of Permacol Collagen Paste in the Treatment of Anorectal Fistulas.
A Randomised, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553
in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy.
An Open-Label Study for Previously Treated Ataluren (PTC124?)
Patients with Nonsense Mutation Dystrophinopathy
A phase III, multi-centre, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in
combination with human Chorionic Gonadotropin (hCG) in inducing increased testicular volume and spermatogenesis in adult
A Randomised, Double-blind, Active Treatment Study to Induce Clinical Response and/or
GSK1605786A in Subjects with Moderately-to-Severely Active Crohn?s DiseaseA Post market clinical study evaluating the safety, device performance and possible emergent risks of Celotres in
the improvement of wound healing and the resulting scar consequences following suturing of a wound. A Phase 3b open-label historically controlled study to assess the safety and efficacy of two
of AA4500 in adult subjects with multiple Dupuytren's contractures with palpable cords.
A phase3, multicentre, randomized, double-blind, parallel
assess the efficacy and safety of reparixin in pancreatic islet transplantationNon-interventional study on the
A Global Comparative Observational Study in Rheumatoid Arthritis (RA) Patients
who are treated with a TNF Inhibitor or Tocilizumab as the first Biologic Therapy
Trial consisting of an 8-week double-blind placebo-controlled
followed by a 16-week openA 6-month study of inhaled fluticasone propionate/salmeterol combination versus inhaled fluticasone
propionate in the treatment of 6,200 paediatric subjects 4-11 years old with persistent asthma.
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter
Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma
Short course daily prednisolone therapy at the time of upper respiratory tract
12/NW/0766 infection in children Available
with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study
Outcome after StrokeXANTUS-Xarelto? on Prevention of Stroke and Non-Central Nervous System
12/WS/0216 Systemic Embolism in Available
Patients with Non-Valvular Atrial Fibrillation: A Non-Interventional StudyWOLLF - Wound
The administration of Parathyroid hormone affects functional recovery from pertrochanteric fractured neck of
femur: A prospective randomised comparative pilot study with blinded objective functional outcome assessment.
Management of Distal Arm Pain. Fractures and Bisphosphonates: A double-blind, randomised controlled
alendronic acid on healing and clinical outcomes of wrist fracturesPilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of
Significant Renal Injury after Kidney Transplantation from Donors after Cardiac Death
A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the
(OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy.
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic
Uremic Syndrome (aHUS) Patients Treated with Eculizumab in a Prior Clinical Study
A Prospective Multicenter Randomized Study Comparing Photoselective
Prostate for the Treatment of Benign Prostatic Hyperplasia (Goliath)
A Phase III, multicentre, randomized, double-blind clinical study,
PGL4001 for the long-term management of symptomatic uterine fibroids
TMC435HPC3001: A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs.
combination with PegIFNa-2a and ribavirin, in chronic hepatitis C genotype-1 infected subjects who were null orA Phase 3,
A phase II/III, multi centre, partially randomised, open label trial investigating safety
demand and prophalactic treatment with BAY 94-9027 in Severe Hemophilia A
A Phase III Prospective, Two-Cohort Non-Randomized, Multi-Centre, Multinational, Open Label Study to Assess the Safety of Assisted- and Self-
Administered Subcutaneous Trastuzumab as Adjuvant Therapy in Patients with Operable Her2-Positive Early Breast CaA Phase III, randomized, double-blinded study comparing the combination of the BRAF inhibitor, dabrafenib and the
trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIC) or metastatic (Stage IV)
A Multicenter, Single arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related
Colorectal Cancer (mCRC) Previously Treated with an Oxaliplatin-Containing Regimen
An Observational Study Of Avastin? (Bevacizumab) In Combination With
Treatment Of First Line Metastatic Colorectal Adenocarcinoma. A Multicentre, Open-label, Single-arm Study of Pertuzumab in Combination with Trastuzumab and a Taxane in First Line
Treatment with HER2-Positive Advanced (Metastatice or Locally Advanced Recurrent) Breast Cancer
An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and
Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237)
Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
A multicentre, open label, randomized Phase II trial of the MEK inhibitor Pimasertib or Dacarbazine in
previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanomaA Phase 3 Randomized, Open-Label Study of Ponatinib versus
Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
A Phase 3, Randomized, DoubleBlind, PlaceboControlled Study Evaluating the Efficacy and Safety of
GS 1101 (CAL 101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia
A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized,
driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients w
A 24-month, phase IIIb, randomi active-controlled, three-arm, multicenter study assessing the efficacy and safety of an
criteria driven PRN dosing regimen with 0.5 mg ranibizumab intravitreal injection applied as monotherapy or wi
Progressive Multiple SclerosisA descriptive study of Relapsing-Remitting Multiple Sclerosis (RRMS) treated with first disease modifying therapies
clinical practice: patterns of clinical decision making and the patient experience of relapseEvaluation of Xience Prime or Xience V versus Coronary Artyert Bypass
Effectiveness of Left Main Revascularization
Leaders Free: a prospective randomized comparison of the biofreedomtm
coated stent versus the gazelle? bare metal stent in patients at high risk for bleeding
A randomized, double-blind, parallel-group, 26-week study comparing the efficacy and safety of indacaterol (Onbrez?
o.d.) with salmeterol/fluticasone propionate (Seretide? Accuhaler? 50 ?g/500 ?g b.i.d.) in patients with moderate chroni
A Phase 3, Randomized, Single-blind, Controlled Trial
CDEB025A2313: A multi-centre 3-year follow-up study to assess the viral activity in patients
sustained virologic response in Novartis-sponsored Alisporivir-studies for chronic Hepatitis C patientsCDEB025A2312: Follow up study for
DEB025 SVR24 Hepatitis C patientsA Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of
Oral BC1036 in the Management of Cough. Sponsor code: BC1036-001, (HCR: 1780/BCO).
A 12-week, multi-centre, randomised, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the
NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe COPD.
A randomised, double-blind, double-dummy, placebo and active-controlled, three-way crossover study to
12/NW/0454 evaluate the safety, Available
tolerability and efficacy of 28-day inhaled CHF 6001 DPI (1200 ?g daily) in subjects with COPD
A randomised double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different total daily
propionate inhaled from a new dry powder inhaler in subjects with severe persistent asthma requiring oral
A phase III randomised, partially double-blind and placebo-controlled study of BI 207127 in combination with faldaprevir and
ribavirin for chronic genotype 1 hepatitis C infection in an extended population of treatment na?ve patients that includes those i
A Phase III, International, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Event Driven Study to Compare the Time to
First Clinical Worsening in Subjects with Pulmonary Arterial Hypertension Receiving UT-15C in Combination with PDE5-1 or ERA
Open-Label Extension Study of UT-15C in Subjects with
Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
A randomised, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment
cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Diseas
Investigation of Flow Altered, Short Transcervical Carotid Artery Stenting in
Patients with Significant Carotid Artery Disease with Filter
A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized,
driven PRN dosing regimen with 0.5-mg ranibizumab intravitreal injections applied as monotherapy in patients w
A 24-month, phase IIIb, randomi active-controlled, three-arm, multicenter study assessing the efficacy and safety of an
criteria driven PRN dosing regimen with 0.5 mg ranibizumab intravitreal injection applied as monotherapy or wi
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of an Investigational Eye
Drop Formulation with OPTIVE? Unit-Dose for 3 Months in Subjects with Dry Eye Disease
Acta Orthop. Belg. , 2007, 73 , 795-798 Brucellar arthritis of the knee : A case report with delayed diagnosis From Universitair Ziekenhuis Brussel, Brussels, Belgium Brucellar septic arthritis has become extremely rare milk and infected milk products ( 7 ). It is a systemic in Western developed countries since bovine brucel- infectious disease with a broad spectrum of clinical
MINISTERE DE LA JEUNESSE, DE L’EDUCATION Christel GENTIL Pour l’obtention du diplôme de l’Ecole Pratique des Hautes Etudes TITRE : Toxicité des médicaments anti-VIH sur le tissu adipeux à l’origine des causes du syndrome mixte de lipodystrophie Soutenu le devant le jury suivant : Dr Lacour Bernard - Président Dr Demignot Sylvie - Rapporteur Dr Feve Bruno - Examinat